A new clinical trial listing for survodutide was posted on October 2, 2026. The study, titled "SYNCHRONIZE-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight," is registered under identifier NCT07855900.
The trial is listed as Phase 3 and its current status is not yet recruiting. According to the registration, the study aims to examine whether survodutide helps adults with overweight or obesity, who do not have diabetes, lose weight.
No results, enrollment numbers, or outcome data have been posted for this trial at this time. The listing reflects only the trial's design and planned scope as registered. Survodutide remains classified as an unapproved compound under research investigation, and this listing does not indicate any change to that regulatory status.
Readers interested in the broader context of survodutide research can consult the compound overview for additional background.